BPH로 인한 LUTS 치료를 위한 Omega 시스템의 안전성, 내약성 및 유효성 평가 (Omega)
양성 전립선 비대증으로 인한 하부 요로 증상 치료를 위한 오메가 시스템의 안전성, 내약성 및 효능 평가
This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device. The Omega arc-shaped implant is inserted by the Omega delivery system into the prostate tissue of subjects to relieve lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The study will first evaluate the Omega system on patients undergoing prostatectomy, which is not indicated for the device.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Tbilisi, 그루지야
- Tbilisi Heart Center
-
Tbilisi, 그루지야
- Todua Clinic
-
Tbilisi, 그루지야, 0159
- N(N)LE New Vision University Hospital
-
Tbilisi, 그루지야
- Israeli-Georgian Medical Research Clinic Healthycore
-
Tbilisi, 그루지야
- JSC L.Managadze National Center of Urology
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Stage 1
Inclusion Criteria:
- Male ≥50 years of age and ≤ 80 years old.
- Will undergo planned prostatectomy.
- Participant understands and is willing to the informed consent form.
- Prostate Volume between 30cc and 80cc.
- Prostate length ≥ 3cm
Exclusion Criteria:
-
Unable to comply with the clinical protocol.
-
Vulnerable population such as inmates or developmentally delayed individuals.
-
Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure, such as:
- Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy is not prohibited).
- Use of alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
- Use of 5-α-reductase inhibitors within 6 months of pre-treatment (baseline) evaluation.
-
American Society of Anesthesiologists score (ASA) > 3.
-
Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.
-
Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.
-
Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.
-
Previous rectal surgery, other than hemorrhoidectomy
-
Current gross hematuria.
-
Known allergy to nickel or titanium or stainless steel.
Stage 2
Inclusion Criteria:
- Male ≥50 years old.
- Suspected symptomatic benign prostatic hyperplasia (BPH).
- International Prostate Symptom Score (IPSS) >13.
- Peak flow rate ≤ 12 ml/sec (with voided volume ≥ 125ml).
- Participant understands and is willing to the informed consent form.
- Prostate Volume between 30cc and 80cc.
- Prostate length ≥ 3cm and ≤ 5cm
Exclusion Criteria:
-
Diagnosed or suspected prostate cancer. If suspected, prostate cancer must be ruled out.
-
Concomitant participation in another interventional study.
-
Unable to comply with the clinical protocol including all the follow-up requirements.
-
Vulnerable population such as inmates or developmentally delayed individuals.
-
Significant comorbidities which would affect study participation.
-
Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure ,such as:
- Use of concomitant medications (e.g., anticholinergics, antispasmodics, or antidepressants) affecting bladder function.
- Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure; low dose aspirin therapy not prohibited.
- Alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
- Taking 5-alpha reductase inhibitors (5-ARI) within 6 months (3 months for type II 5-ARI) of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study).
- Patient is taking steroids. [Note: Patients approved for the trial who are using the above medications will continue using them after the trial, except for Alpha blockers.]
-
Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.
-
Compromised renal function due to obstructive uropathy.
-
Active Urinary Tract Infection (UTI).
-
Obstructive or protruding median lobe.
-
American Society of Anesthesiologists score (ASA) > 3.
-
Known neurogenic bladder or neurological disorders that might affect bladder or function.
-
Recent myocardial infarction (less than three months).
-
Concomitant bladder stones.
-
Current gross hematuria.
-
Active or history of epididymitis within the past 3 months.
-
Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.
-
Confirmed or suspected malignancy of bladder.
-
History or presence of strictures in the anterior urethra or bladder neck contracture or detrusor muscle spasms.
-
Other urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.
-
Bacterial prostatitis within the last 12 months.
-
Previous rectal surgery, other than hemorrhoidectomy.
-
Current uncontrolled diabetes (i.e., hemoglobin A1c ≥ 9%).
-
Known allergy to nickel or titanium or stainless steel.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 오메가 절차
|
The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant. The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Primary Safety (Stage 1 and Stage 2) - Incidence and severity of procedural and device related adverse events.
기간: 12 Months
|
Incidence and severity of procedural and device related adverse events. |
12 Months
|
|
Primary Safety (Stage 2) - Incidence of post-operative catheterization after 7 days, up to 14 days.
기간: 2 weeks
|
Incidence of post-operative catheterization after 7 days, up to 14 days. |
2 weeks
|
|
Efficacy (Stage 2) - Change in urinary related symptom
기간: 3 Months
|
Improvement in urinary related symptoms as evidenced by at least 30% decrease in International Prostate Symptom Score (A score of 0-7 indicates mild symptoms, 8-19 indicates moderate symptoms and 20-35 indicates severe symptoms) |
3 Months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
효능(2단계) - 요속 측정 Qmax에서 최소 25%의 증가로 입증되는 최대 요속 개선
기간: 1개월, 3개월, 6개월, 12개월
|
1개월, 3개월, 6개월, 12개월
|
|
|
탐색적 - 공극 후 잔류(PVR) 테스트의 변화
기간: 1개월, 3개월, 6개월, 12개월
|
1개월, 3개월, 6개월, 12개월
|
|
|
탐색적 - 방광경으로 평가되는 염증 발생률
기간: 6 개월
|
6 개월
|
|
|
Exploratory - 방광경으로 평가한 Omega 범위
기간: 6 개월
|
6 개월
|
|
|
탐색적 - 기준선과 비교한 PSA 변화
기간: 1개월, 6개월, 12개월
|
1개월, 6개월, 12개월
|
|
|
탐색적 - 기준선에서 BPHII 점수 변경
기간: 1개월, 3개월, 6개월, 12개월
|
1개월, 3개월, 6개월, 12개월
|
|
|
하부 요로 증상(LUTS)에 대한 반복적인 침습적 치료 발생률 또는 BPH 증상 치료를 위한 새로운 약물의 투여량 증가 또는 시작
기간: 12 개월
|
12 개월
|
|
|
장치 제거 빈도
기간: 12 개월
|
12 개월
|
|
|
Functionality (Stage 1) - Location and orientation of Omega implant in the prostate before prostatectomy is as planned: Yes/No
기간: Procedure day
|
Evaluating whether the outcome of the Omega implant's location and orientation turned out as the surgeon planned prior to the Omega procedure. |
Procedure day
|
|
Functionality (Stage 1) - Location and depth Omega incision in the excised prostate is as planned: Yes/No.
기간: Procedure day
|
Evaluating whether the Omega incision location and depth outcome turned out as the surgeon planned prior to the Omega procedure. |
Procedure day
|
|
Usability (Stage 1 and Stage 2) - Evaluate the usability of the device and entire process
기간: Procedure day
|
Evaluate the usability of the device and the entire process using the usability questionnaire (The highest score of 60 indicates that the device is extremely user-friendly, while the lowest score of 12 indicates that the device is very difficult to use) |
Procedure day
|
|
Efficacy (Stage 2) - Improvement in urinary related symptoms
기간: 1 Months, 6 Months and 12 months
|
Evaluate the improvement in urinary-related symptoms as evidenced by a decrease of at least 30% in the IPSS score. (A score of 0-7 indicates mild symptoms, 8-19 indicates moderate symptoms and 20-35 indicates severe symptoms) |
1 Months, 6 Months and 12 months
|
|
Exploratory - Change in sexual function assessments from screening to 3, 6 and 12 months using the International Index of Erectile Function (IIEF) and Male Sexual Health Questionnaire for Ejaculatory Function (MSHQ-EjD).
기간: 3 Months, 6 Months and 12 months
|
The IIEF-15 score ranges from 6 to 75 and is used to classify erectile dysfunction (ED). An MSHQ-EjD score of 20 indicates the absence of ejaculatory dysfunction, while a score of 0 indicates a high level of ejaculatory dysfunction. |
3 Months, 6 Months and 12 months
|
|
Exploratory - Change in VAS pain score
기간: Procedure day, 1-2 weeks and 1 month
|
A VAS pain score of (0-1 mm) indicates no pain,(2-4 mm) - mild pain, (4-7 mm) - moderate pain, and (7-10 mm) - severe pain. |
Procedure day, 1-2 weeks and 1 month
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Frank Mastandrea, Dr, Board Member and Medical Director
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- PA-CP-22
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .